Troy A. Ignelzi Karuna Therapeutics, Inc. (KRTX) insider trading activity

Troy A. Ignelzi is Chief Financial Officer of Karuna Therapeutics, Inc.. Currently has a direct ownership of 30,487 shares of KRTX, which is worth approximately $0. The most recent transaction as insider was on Feb 15, 2022, when has been sold 1,500 shares (Common Stock) at a price of $111.14 per share, resulting in proceeds of $166,710. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 30.5K

0% 3M change

0% 12M change

Total Value Held $0

Troy A. Ignelzi Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 15 2022	SELL Open market or private sale	$166,710 $111.14 p/Share	1,500 Reduced 5.67%	24,970 Common Stock
Feb 15 2022	BUY Exercise of conversion of derivative security	$13,800 $9.2 p/Share	1,500 Added 5.36%	26,470 Common Stock
Dec 21 2021	BUY Exercise of conversion of derivative security	$64,124 $9.2 p/Share	6,970 Added 21.82%	24,970 Common Stock
Nov 08 2021	SELL Open market or private sale	$2,056,320 $152.32 p/Share	13,500 Reduced 42.86%	18,000 Common Stock
Nov 08 2021	BUY Exercise of conversion of derivative security	$124,200 $9.2 p/Share	13,500 Added 30.0%	31,500 Common Stock
Sep 10 2021	SELL Open market or private sale	$228,095 $120.05 p/Share	1,900 Reduced 9.55%	18,000 Common Stock
Sep 10 2021	BUY Exercise of conversion of derivative security	$17,480 $9.2 p/Share	1,900 Added 8.72%	19,900 Common Stock
Sep 09 2021	SELL Open market or private sale	$60,025 $120.05 p/Share	500 Reduced 2.7%	18,000 Common Stock
Sep 09 2021	BUY Exercise of conversion of derivative security	$4,600 $9.2 p/Share	500 Added 2.63%	18,500 Common Stock
Sep 08 2021	SELL Open market or private sale	$901,284 $118.59 p/Share	7,600 Reduced 29.69%	18,000 Common Stock
Sep 08 2021	BUY Exercise of conversion of derivative security	$69,920 $9.2 p/Share	7,600 Added 29.01%	18,600 Common Stock
Aug 20 2021	BUY Exercise of conversion of derivative security	$46,000 $9.2 p/Share	5,000 Added 21.74%	18,000 Common Stock
Jun 16 2021	SELL Open market or private sale	$335,192 $128.92 p/Share	2,600 Reduced 16.67%	13,000 Common Stock
Jun 16 2021	BUY Exercise of conversion of derivative security	$23,920 $9.2 p/Share	2,600 Added 16.3%	13,352 Common Stock
Jun 14 2021	SELL Open market or private sale	$119,268 $132.52 p/Share	900 Reduced 6.47%	13,000 Common Stock
Jun 14 2021	BUY Exercise of conversion of derivative security	$8,280 $9.2 p/Share	900 Added 6.08%	13,900 Common Stock
May 12 2021	SELL Open market or private sale	$24,000 $120.0 p/Share	200 Reduced 1.52%	13,000 Common Stock
May 12 2021	BUY Exercise of conversion of derivative security	$1,840 $9.2 p/Share	200 Added 1.49%	13,200 Common Stock
May 10 2021	SELL Open market or private sale	$770,490 $110.07 p/Share	7,000 Reduced 35.0%	13,000 Common Stock
May 10 2021	BUY Exercise of conversion of derivative security	$64,400 $9.2 p/Share	7,000 Added 25.93%	20,000 Common Stock
Feb 16 2021	SELL Open market or private sale	$1,195,700 $119.57 p/Share	10,000 Reduced 43.48%	13,000 Common Stock
Feb 16 2021	BUY Exercise of conversion of derivative security	$92,000 $9.2 p/Share	10,000 Added 30.3%	23,000 Common Stock
Jan 08 2021	SELL Open market or private sale	$835,920 $104.49 p/Share	8,000 Reduced 38.1%	13,000 Common Stock
Jan 08 2021	BUY Exercise of conversion of derivative security	$73,600 $9.2 p/Share	8,000 Added 27.59%	21,000 Common Stock
Dec 29 2020	BUY Exercise of conversion of derivative security	$73,600 $9.2 p/Share	8,000 Added 38.1%	13,000 Common Stock

Also insider at

CINC

CinCor Pharma, Inc. Healthcare

Director

CTNM

Contineum Therapeutics, Inc.

Director

RAPP

Rapport Therapeutics, Inc.

Chief Financial Officer

TAI

Troy A. Ignelzi

Chief Financial Officer

Boston, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KRTX shares.

Notify only if

Value

Insider Trading

Get notified when an Karuna Therapeutics, Inc. insider buys or sells KRTX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Karuna Therapeutics, Inc.

Track Activities on KRTX

Account